Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

8. februar 2019 opdateret af: Daiichi Sankyo, Inc.

A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation

This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1146

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brussels, Belgien
      • Genk, Belgien
      • Banja Luka, Bosnien-Hercegovina
      • Mostar, Bosnien-Hercegovina
      • Sarajevo, Bosnien-Hercegovina
      • Tuzla, Bosnien-Hercegovina
    • Alberta
      • Calgary, Alberta, Canada
      • Edmonton, Alberta, Canada
    • British Columbia
      • Alberta, British Columbia, Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada
    • Ontario
      • Oshawa, Ontario, Canada
      • Thunder Bay, Ontario, Canada
    • Quebec
      • Montreal, Quebec, Canada
      • Sherbrooke, Quebec, Canada
      • Antofagasta, Chile
      • Osorno, Chile
      • Santiago, Chile
      • Temuco, Chile
      • Arkhangelsk, Den Russiske Føderation
      • Barnaul, Den Russiske Føderation
      • Chelyabinsk, Den Russiske Føderation
      • Ivanovo, Den Russiske Føderation
      • Kaliningrad, Den Russiske Føderation
      • Kazan, Den Russiske Føderation
      • Kemerovo, Den Russiske Føderation
      • Krasnodar, Den Russiske Føderation
      • Krasnoyarsk, Den Russiske Føderation
      • Moscow, Den Russiske Føderation
      • N.Novgorod, Den Russiske Føderation
      • Novosibirsk, Den Russiske Føderation
      • Orenburg, Den Russiske Føderation
      • Penza, Den Russiske Føderation
      • Perm, Den Russiske Føderation
      • Rostov on Don, Den Russiske Føderation
      • Samara, Den Russiske Føderation
      • Saratov, Den Russiske Føderation
      • St. Petersburg, Den Russiske Føderation
      • Tomsk, Den Russiske Føderation
      • Tula, Den Russiske Føderation
      • Tyumen, Den Russiske Føderation
      • Volgograd, Den Russiske Føderation
      • Yaroslavl, Den Russiske Føderation
    • Alabama
      • Huntsville, Alabama, Forenede Stater
    • California
      • Anaheim, California, Forenede Stater
      • Beverly Hills, California, Forenede Stater
      • Stockton, California, Forenede Stater
    • Florida
      • Orlando, Florida, Forenede Stater
      • Sarasota, Florida, Forenede Stater
    • Georgia
      • Atlanta, Georgia, Forenede Stater
      • Canton, Georgia, Forenede Stater
    • Indiana
      • Fort Wayne, Indiana, Forenede Stater
    • Iowa
      • Iowa City, Iowa, Forenede Stater
    • Michigan
      • Cadillac, Michigan, Forenede Stater
    • Montana
      • Kalispell, Montana, Forenede Stater
    • Nebraska
      • Fremont, Nebraska, Forenede Stater
    • New Mexico
      • Santa Fe, New Mexico, Forenede Stater
    • New York
      • Albany, New York, Forenede Stater
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater
      • Pottstown, Pennsylvania, Forenede Stater
      • Sellersville, Pennsylvania, Forenede Stater
    • Texas
      • Dallas, Texas, Forenede Stater
    • Utah
      • Salt Lake City, Utah, Forenede Stater
    • Washington
      • Bellevue, Washington, Forenede Stater
      • Minsk, Hviderusland
      • Daugavpils, Letland
      • Riga, Letland
      • Ventspils, Letland
      • Cordoba, Mexico
      • Guadalajara Jalisco, Mexico
      • Mexico City, Mexico
      • Chisinau, Moldova, Republikken
      • Bardejov, Slovakiet
      • Bratislava, Slovakiet
      • Kosice, Slovakiet
      • Lucenec, Slovakiet
      • Presov, Slovakiet
      • Cherkassy, Ukraine
      • Chernigov, Ukraine
      • Chernivtsy, Ukraine
      • Dnepropetrovsk, Ukraine
      • Donetsk, Ukraine
      • Ivano-Frankovsk, Ukraine
      • Kiev, Ukraine
      • Lutsk, Ukraine
      • Lviv, Ukraine
      • Odessa, Ukraine
      • Poltava, Ukraine
      • Ternopil, Ukraine
      • Vinnitsa, Ukraine
      • Zaporozhye, Ukraine

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female, 18 to 80 years old.
  2. Able to provide written informed consent.
  3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)
  4. A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2

Exclusion Criteria:

  1. Subjects with mitral valve disease or previous valvular heart surgery
  2. Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin
  3. Known or suspected hereditary or acquired bleeding or coagulation disorder

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 1
DU-176b 30mg tablet once daily
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
Eksperimentel: 2
DU-176b 60mg once daily
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
Eksperimentel: 3
DU-176b 30mg b.i.d.
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
Eksperimentel: 4
DU-176b 60mg tablets two times a day
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
Aktiv komparator: 5
warfarin tablets
warfarin tablets

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adjudicated Incidence of Bleeding Events
Tidsramme: 3 months
Adjudicated Incidence of Bleeding Events during treatment period
3 months
Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)
Tidsramme: 3 months
liver enzyme (ALT and/or AST) and/or bilirubin (TBL) abnormalities
3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Major Adverse Cardiac Events MACE)
Tidsramme: 3 months
MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition
3 months
Effects on Biomarker D-dimer
Tidsramme: 3 months
Mean (SD) change from baseline in D-dimer
3 months
Effects on Biomarker Prothrombin Fragments
Tidsramme: 3 months
Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2)
3 months
Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b
Tidsramme: 3 months
Median (min, max) values of Cmin,ss; Cmax,ss
3 months
Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b
Tidsramme: 3 months
Median (min, max) values of AUCss
3 months
Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b
Tidsramme: Day 28
Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose.
Day 28
Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b
Tidsramme: Day 28
Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose.
Day 28
Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b
Tidsramme: Day 28

Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose.

PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition.

Day 28
Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b
Tidsramme: Day 28
Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose.
Day 28
Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b
Tidsramme: Day 28
Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose.
Day 28

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juni 2007

Primær færdiggørelse (Faktiske)

1. juni 2008

Studieafslutning (Faktiske)

1. juni 2008

Datoer for studieregistrering

Først indsendt

18. juli 2007

Først indsendt, der opfyldte QC-kriterier

18. juli 2007

Først opslået (Skøn)

20. juli 2007

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. februar 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. februar 2019

Sidst verificeret

1. marts 2015

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD-delingstidsramme

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD-delingsadgangskriterier

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner